
[Federal Register Volume 84, Number 23 (Monday, February 4, 2019)]
[Notices]
[Pages 1469-1470]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-00847]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2018-P-1877 and FDA-2018-P-3730]


Determination That ESBRIET (Pirfenidone) Film Coated Tablets, 534 
Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or 
Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) has 
determined that ESBRIET (pirfenidone), film coated tablets, 534 
milligrams (mg), was not withdrawn from sale for reasons of safety or 
effectiveness. This determination will allow FDA to approve abbreviated 
new drug applications (ANDAs) for pirfenidone, film coated tablets, 534 
mg, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Daniel Gottlieb, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 51, Rm. 6208, Silver Spring, MD 20993-0002, 301-
796-6650.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) 
(the 1984 amendments), which authorized the approval of duplicate 
versions of drug products under an ANDA procedure. ANDA applicants 
must, with certain exceptions, show that the drug for which they are 
seeking approval contains the same active ingredient in the same 
strength and dosage form as the ``listed drug,'' which is a version of 
the drug that was previously approved. ANDA applicants do not have to 
repeat the extensive clinical testing otherwise necessary to gain 
approval of a new drug application (NDA).
    The 1984 amendments include what is now section 505(j)(7) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which 
requires FDA to publish a list of all approved drugs. FDA publishes 
this list as part of the ``Approved Drug Products With Therapeutic 
Equivalence Evaluations,'' which is known generally as the ``Orange 
Book.'' Under FDA regulations, drugs are removed from the list if the 
Agency withdraws or suspends approval of the drug's NDA or ANDA for 
reasons of safety or effectiveness or if FDA determines that the listed 
drug was withdrawn from sale for reasons of safety or effectiveness (21 
CFR 314.162).
    A person may petition the Agency to determine, or the Agency may 
determine on its own initiative, whether a listed drug was withdrawn 
from sale for reasons of safety or effectiveness. This determination 
may be made at any time after the drug has been withdrawn from sale, 
but must be made prior to approving an ANDA that refers to the listed 
drug (Sec.  314.161 (21 CFR 314.161)). FDA may not approve an ANDA that 
does not refer to a listed drug.
    ESBRIET (pirfenidone), film coated tablets, 534 mg, is the subject 
of NDA 208780, held by Genentech, Inc., and initially approved on 
January 11, 2017. ESBRIET is indicated for the treatment of idiopathic 
pulmonary fibrosis. ESBRIET (pirfenidone), film coated tablets, 534 mg, 
is currently listed in the ``Discontinued Drug Product List'' section 
of the Orange Book. Laurus Labs Ltd. submitted a citizen petition dated 
May 14, 2018 (Docket No. FDA-2018-P-1877), and Aziant Drug Research 
Solutions Pvt. Ltd. Submitted a citizen petition dated October 1, 2018 
(FDA-2018-P-3730), under 21 CFR 10.30, requesting that the Agency 
determine whether ESBRIET (pirfenidone), film coated tablets, 534 mg, 
was withdrawn from sale for reasons of safety or effectiveness.
    After considering the citizen petitions and reviewing Agency 
records and based on the information we have at this time, FDA has 
determined under Sec.  314.161 that ESBRIET (pirfenidone), film coated 
tablets, 534 mg, was not withdrawn for reasons of safety or 
effectiveness. The petitioners have identified no data or other 
information suggesting that this drug product was withdrawn for reasons 
of safety or effectiveness. We have carefully reviewed our files for 
records concerning the withdrawal of ESBRIET (pirfenidone), film coated 
tablets, 534 mg, from sale. We have also independently evaluated 
relevant literature and data for possible postmarketing adverse events. 
We have found no information that would indicate that this drug product 
was withdrawn from sale for reasons of safety or effectiveness.
    Accordingly, the Agency will continue to list ESBRIET 
(pirfenidone), film coated tablets, 534 mg, in the ``Discontinued Drug 
Product List'' section of the Orange Book. The ``Discontinued Drug 
Product List'' delineates, among other items, drug

[[Page 1470]]

products that have been discontinued from marketing for reasons other 
than safety or effectiveness. ANDAs that refer to this drug product, 
may be approved by the Agency as long as they meet all other legal and 
regulatory requirements for the approval of ANDAs. If FDA determines 
that labeling for this drug product should be revised to meet current 
standards, the Agency will advise ANDA applicants to submit such 
labeling.

    Dated: January 17, 2019.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2019-00847 Filed 2-1-19; 8:45 am]
 BILLING CODE 4164-01-P


